This biotechnology company specializes in the research and development of novel molecular glue degraders. They utilize proprietary molecular glue discovery platforms to advance drug candidates across oncology, autoimmune, and genetic disease indications. The company focuses on developing first-in-class and best-in-class molecular glue therapeutics to address unmet clinical needs.
Funding
$22M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, particularly in oncology and immunology, lack effective treatments due to the inability to target and eliminate specific disease-causing proteins. Traditional drug development approaches often struggle to address these targets with sufficient selectivity and efficacy, leaving significant unmet medical needs.
Solution
GluBio Therapeutics is developing small-molecule targeted protein degraders (TPDs) designed to selectively eliminate disease-causing proteins. The company's proprietary TPD discovery platform enables the identification and optimization of highly selective degraders. By harnessing the power of targeted protein degradation, GluBio aims to create innovative medicines that offer enhanced therapeutic efficacy and address previously undruggable targets in areas such as oncology and immunology. The company is advancing a diverse pipeline of these degraders across multiple therapeutic areas.
Target Audience
The primary target audience includes patients with cancer and immunological disorders who have unmet medical needs, as well as pharmaceutical companies seeking innovative drug candidates for these diseases.
Features
- Proprietary TPD discovery platform for identifying novel protein degraders
- Robust screening capabilities to ensure high selectivity and efficacy
- Focus on developing small-molecule degraders for enhanced drug-like properties
- Pipeline of degraders targeting disease-causing proteins in oncology and immunology
- Capability to address previously undruggable targets